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Asherman syndrome is a debatable topic in gynaecological field and there is no clear consensus about management
and treatment. It is characterized by variable scarring inside the uterine cavity and it is also cause of menstrual
disturbances, infertility and placental abnormalities. The advent of hysteroscopy has revolutionized its diagnosis and
management and is therefore considered the most valuable tool in diagnosis and management. The aim of this review
is to explore the most recent evidence related to this condition with regards to aetiology, diagnosis management and
follow up strategies.
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Although the first case of intrauterine adhesion was
published in 1894 by Heinrich Fritsch, it was only after
54 years that a full description of Asherman syndrome
(AS) was carried out by Israeli gynaecologist Joseph
Asherman. Specifically, he identified this pathology in 29
women who showed amenorrhea with stenosis of internal
cervical ostium [1]. The author speculated that such a
manifestation could be a consequence of endometrium
trauma. Two years later, he published another case
series of intrauterine adhesions, this time involving
the uterine cavity and characterized by evident filling
defects during hysterography [2].
Intrauterine adhesions can lead to partial or complete
dysfunction of the endometrium with impairment of fer-
tility and menstrual pattern (amenorrhea and hypome-
norrhea) (Figure 1). When the adhesions are exclusively
located in the lower uterine tract and functioning endo-
metrium persists, this syndrome can also cause severe
pelvic pain and retrograde menstruation.
Pregnant or early pregnant uterus seems to be more
susceptible to develop uterine scarring after curettage.
Nonetheless any uterine insult or trauma following even
less invasive surgical procedure can lead to intrauterine
adhesions development.* Correspondence: confale@hotmail.it
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reproduction in any medium, provided the orThe impact of the AS on pregnancy is well docu-
mented with a high rate of infertility, miscarriage, poor
implantation following in vitro fertilization and abnor-
mal placentation [3,4].
It is important to underline that there is plenty of
cases reported in literature where the presence of intra-
uterine adhesion (IUA) is not associated with any symp-
toms. Under these circumstances, some authors believe
that the term of AS should be avoided [3].
Hence, AS should be defined by the presence of adhe-
sions inside uterine cavity and/or endocervix whereby
derives one or more clinical manifestations such as
amenorrhea, hypomenorrhea, recurrent pregnancy loss,
infertility and history of abnormal placentation.
The highest frequency of this condition was reported
in Israel, Greece and South America as well as in various
European countries [5]. This kind of distribution does
not seem related to any specific geographic factor [5]. It
is evident that the introduction of hysteroscopy in the
diagnosis of intrauterine lesions has helped us to realise
that IUA is much more frequent than we had previously
thought [6]. Moreover, the incidence of this pathology
seems to be significantly influenced by the number of
abortions performed, the high incidence of genital tuber-
culosis in some countries and the different criteria used
to detect intrauterine adhesions.
The aim of this review is to summarise the most re-
cent evidences with regard to aetiology, diagnosis, classi-
fication and management.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Intrauterine adhesions: hysteroscopic appearance.
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Data regarding pathophysiology of AS and IUA are still
limited in literature. Electric microscopic evaluation of
endometrial ghiandolar cells of women affected by se-
vere AS revealed significant sub-cellular modifications
such as ribosome lost, mitochondria swelling vascular
closure and hypoxic cellular modifications [7].
Some researchers have focused their attention towards
endometrial vascularity changes following endometrial
trauma. An impaired vascularity of both endometrium
and myometrium has been demonstrated by using pelvic
angiography in patients with dense IUA [8].
In a recent prospective study involving 40 patients
with AS, an high impedance of spiral artery was ob-
served. The authors hypothesized that these phenomena
could explain the reduced endometrial receptivity and
regeneration in these women [9]. In addition, in patients
responding to treatment, vascular endothelial growth
factor (VEGF) and microvessel density are significantly
increased, thus confirming that angiogenesis and revas-
cularization may play an important role in endometrial
regeneration [7].
A possible involvement of adhesion related cytokines
in the pathogenesis of IUA (such as b-fibroblast growth
factor, platelet derived growth factor and transforming
growth factor type 1), was also recently suggested [10].
Although not clearly identified, a possible genetic fac-
tor could explain why certain patients show more fre-
quent adhesions incidence and recurrence, or why IUA
adhesions can develop even without any surgical trauma
or trigger event [3,5,6].
Table 1 illustrates the most common risk factors in-
volved in AS: it also shows that the condition is usually
related to iatrogenic trauma to the endometrium. A
major contribution to the identification of the main risk
factors listed in Table 1 was provided by Schenker and
Margalioth in a seminal study published in 1982. Theyevaluated 1856 cases of AS confirming that women who
underwent uterine curettage were at high risk of devel-
oping intrauterine adhesions. Curettage after a miscar-
riage had the highest association with AS (1237 out of
1856 cases) [5]. Moreover, it was reported that when the
curettage is carried out between the 2nd and the 4th post-
partum week, an highest incidence of IUA is detected [6].
It also important to underline the fact that the number
of intrauterine surgical procedure seems to be propor-
tionally related to severity and recurrence of IUA [4].
It is not only curettage of the uterine cavity which
risks AS. More recently, it has become evident that hys-
teroscopic surgery can also have a detrimental effect on
the endometrium. According to the study by Taskin
et al., the hysteroscopic resection of multiple submuco-
sal fibroids has the highest risk of IUA following hyster-
oscopy in a non-post gravid uterus [13].
Considering the limited number of related studies the
role of the infection in the pathogenesis of AS still re-
mains unclear [3,4].
Analysing 171 cases of caesarean sections, Polishuk
et al. found that the 28 women who developed endomet-
ritis did not have an increased incidence of AS com-
pared with those with no infection [16]. Based on this
data, some researchers have raised doubt about the infec-
tion rule in IUA pathogenesis [17]. In addition, there is still
no evidence that antibiotic therapy can exert a favourable
effect after or before surgical treatment of IUA [4].
In spite of this, many authors do believe that the
inflammatory pathway could play an important role on
the pathogenesis of AS, resulting in the release into the
intrauterine environment of factors which stimulate the
formation of fibrotic tissue after endometrial trauma
[18]. In conclusion, the combination of ischemia and
infiammation induced by surgical trauma may constitute
the main trigger for IUA development [3].
Mycobacterium tuberculosis could also involve the
genital tract resulting in severe IUA [5]. In addition,
genital tuberculosis seems to be associated with recur-
rence of IUA and poor prognosis after hysteroscopical
surgery [19]. Schistosoma sp., have also been implicated
in the development of AS, and it has been suggested that
schistosomiasis infection should be ruled out in parts of
the world where it is endemic [20].
Diagnosis
During the last 20 years, the opportunity to explore the
inside of the uterus, provided by the new endoscopic
procedures, has revolutionized diagnosis and manage-
ment of AS. AS and IUA should be suspected in every
woman presenting menstrual problems (hypomenorrhea
or amenorrhea) and/or infertility with history of curettage
or other intrauterine surgery. AS cannot be diagnosed by
simple bimanual pelvic examination, therefore an accurate
Table 1 Asherman syndrome: summary of risk factors
Risk factors Frequency References
Miscarriage curettage 66.7% (1237/1856) Schenker and Margalioth 1982 [5]
Postpartum curettage 21.5% (400/1856) Schenker and Margalioth 1982 [5]
Caesarean section 2% (38/1856) Schenker and Margalioth 1982 [5]
Trophoblastic disease evacuation 0.6% (11/1856) Schenker and Margalioth 1982 [5]
Mullerian duct malformation 16% (7/43) Stillman and Asarkof 1985 [11]
Infection (Genital tuberculosis) 4% (74/1856) Schenker and Margalioth 1982 [5]
Diagnostic curettage 1.6% (30/1856) Schenker and Margalioth 1982 [5]
Abdominal myomectomy 1.3% (24/1856) Schenker and Margalioth 1982 [5]
Uterine artery embolization 14 (7/51) Mara et al. 2007 [12]
Hysteroscopic surgery:
• metroplasty 6% (1/15) Taskin et al. 2000 [13]
• myomectomy (single myoma) 31.3% (10/32) Taskin et al. 2000 [13]
• myomectomy (multiple myomas) 45.5% (9/20) Taskin et al. 2000 [13]
• endometrial ablation 36.4% (8/22) Leung et al. 2003 [14]
Insertion of IUD 0.2% (3/1856) Schenker and Margalioth 1982 [5]
Uterine compressive sutures for post-partum haemorrhage 18.5% (5/27) Ibrahim et al. 2013 [15]
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cavity.
Historically, hysterosalpingography (HSG) has repre-
sented the most widespread diagnostic tool. It is a cost-
effective method to assess tubal patency in women who
suffer from infertility. Usually, AS is characterized by
filling defects described as homogeneous opacity sur-
rounded by sharp edges [21]. In the worst cases, the
uterine cavity appears completely distorted and nar-
rowed, and ostial occlusion may also be evident. How-
ever, the information provided by an HSG is relatively
crude, and it is important to bear in mind that the inves-
tigation has a high false positive rate [3].
Transvaginal ultrasound has a high compliance, and in
many countries it is often used “in office” during gynae-
cological consultation. The ultrasounds image of AS is
characterized by an echo dense pattern with difficult
visualization of endometrium interrupted by one or
more translucent “cyst like” areas [3]. Although, the
diagnostic accuracy of ultrasound has been reported to
be low [22-24], it does allow visualization of the uterine
cavity when a complete obstruction of the cervix pre-
cludes HSG or hysteroscopy. Ultrasound imaging seems
to be significantly influenced by ovulatory cyclical phase
of menstrual cycle [25], therefore some authors suggest
that the best time for the evaluation of endometrium is
during luteal phase of the menstrual cycle [24].
Ultrasound control can also be useful during hystero-
scopic adhesiolysis, in order to prevent uterine injury.
Compared with laparoscopy, ultrasound monitoring is
cheaper, with no difference in the incidence of uterine per-
foration [26]. In addition, some authors have reported itsvalue to predict the outcome of surgical repair by allowing
assessment of residual endometrium: if little or no endo-
metrium is seen during transvaginal scan, the likelihood of
a successful outcome is greatly decreased [27].
Data regarding the value of three-dimensional (3D)
ultrasound in the detection of intrauterine adhesions are
limited. Preliminary data in 2003 showed a specificity of
45% [23]. In a case series of 54 subjects with a high sus-
picion of AS, a significantly higher sensitivity of 3D
ultrasound method was showed [28]. However, until fur-
ther data becomes available, the high cost of 3D ultra-
sound does not justify its use in clinical practice.
The use of saline infusion during the ultrasound scan
(Sonohysterography or SHG) has also been investigated.
Salle et al. reported comparable sensitivity and specifi-
city with the standard HSG [22]. More recently, in a
retrospective study involving 149 cases with intrauterine
anomalies, Acholonu et al. demonstrated a significant
difference in general accuracy (50.3% in HSG group and
81.8% in SHG group) [29].
Another technique combining 3D ultrasound and
intrauterine saline infusion (Three-dimensional sonohys-
terography, 3D-SHG) has recently been proposed for the
diagnosis of intrauterine lesions. 3D-SHG, carried out in
combination with 3D power Doppler (3-DPD), was
found to have sensitivity and specificity of 91.1% and
98.8% respectively for all kinds of intrauterine lesion in-
cluding synechiae [30]. Abou-Salem et al. confirmed
these preliminary results showing comparable diagnostic
efficacy with hysteroscopy [31].
Magnetic resonance imaging (MRI) can be helpful as a
supplementary diagnostic tool, especially when the adhesions
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intensity on T2 weighed-image inside the uterus [32].
Despite the above developments, hysteroscopy remains
the gold standard in the assessment of AS. Table 2 illus-
trates the accuracy of transvaginal ultrasound, HSG and
SHG compared with gold standard hysteroscopic im-
aging (Table 2).
Hysteroscopy provides a real time view of the uterine
cavity, allowing for a meticulous definition of the site,
extent and character of any adhesions, and it is the
optimum tool for assessing the endometrium. Currently,
this technique can be performed in ambulatory setting
with less discomfort than a blind HSG. Hysteroscopy also
makes immediate treatment possible in some favourable
cases [33].
Classification
The extent of any adhesions and its impact on female
reproduction should be evaluated where AS is suspected.
The ideal classification system should include a compre-
hensive description of the adhesions which should be
graded in terms of severity. Finally, it ought to provide a
practical guide for clinicians to achieve optimum treat-
ment and likely outcome.
Since Asherman original description, there have been
many attempts to find the most accurate classification
for IUAs. Toeff and Ballas (1978) were the first authors
who tried to classify AS on the basis of hysterosalpingo-
graphic findings (Table 3) [34]. In the same year, March
et al. introduced for the first time a hysteroscopic classi-
fication of AS (Table 4) [35]. This classification is still
used for its simplicity although it is considered insuffi-
ciently prognostic [36].
Finally, the widely used classification developed on be-
half of the American Fertility Society took into account
the extent of the disease, menstrual pattern and the
morphological feature of the adhesions. Both hysteros-
copy and HSG could be used for this kind of scoring
system (Table 5) [37].
More recently, the classification published in 2000 by
Nasr et al. illustrated an innovative way to classify AS
(Table 6) [36]. This scoring system included not only the
menstrual symptoms but also the obstetric history of the
woman. According to this group, clinical history plays a
more important role than the extent of the adhesions.
The results were compared with the classifications of
March and the ESH showing a good correlation inTable 2 Diagnosis of intrauterine adhesions (Gold standard: h
Approach Sensitivity (%) Specificity (%)
Ultrasound 0.5 95.2
Sonohysterography 75 93.4
Hysterosalpingography 75 95.1women with mild or severe disease, but not in those
with moderate adhesions.
In conclusion, there is still no clear consensus regard-
ing the optimum classification of AS. None of proposed
classification systems seems to offer a valuable repro-
ductive prognosis, as a consequence, further studies are
required [3,4].
Whether the more complex clinicohysteroscopic scor-
ing system is any better than the others remains to be
seen.
Management and treatment of Asherman
syndrome
The treatment strategy of AS could be summarized in
four main steps:
1. Treatment (Dilatation and curettage, hysteroscopy,
hysterotomy)
2. Re-adhesion prevention (Intrauterine device, Uterine
balloon stent, Foley’s catheter, anti-adhesion barriers)
3. Restoring normal endometrium (Hormonal
treatment, stem cells)




Few cases of AS treatment using an open-surgery ap-
proach with transfundal separation of scarring uterine
walls have been mentioned: in some cases an adequate
restoration of menstruation and fertility was obtained
[5,38]. It has been superseded by hysteroscopic tech-
niques, so today this strategy may be adopted only in
extremely complex situation, when the hysteroscopic ap-
proach is not possible or unlikely to succeed, and only
by expert surgeons [3]. The patient should be informed
about the risk of the procedure, and warmed that the
successful restoration of the cavity may not be obtained,
not even with such an aggressive approach [3,5].
Dilatation and curettage
Before the introduction of hysteroscopy, the blind dila-
tion and curettage (D&C) was the treatment of choice
[5]. Nevertheless blind D&C is associated with a high
risk of uterine perforation as well as being a relatively
poor diagnostic tool, with the result that this technique
should be considered obsolete [39].ysteroscopy)
PPV (%) NPV (%)
0.0 95.2 Soares et al. 2000 [24]
42.9 98.3 Soares et al. 2000 [24]
50 98.3 Soares et al. 2000 [24]
Table 3 HSG Classification Toaff and Ballas 1978
Classification Condition
Type 1 Atresia of the internal ostium, without concomitant
corporal adhesions
Type 2 Stenosis of internal ostium, causing almost complete
occlusion without concomitant corporal adhesions
Type 3 Multiple small adhesions in the internal ostium isthmic region
Type 4 Supra isthmic diaphragm causing complete separation
of the main cavity form its lower segment
Type 5 Atresia of the internal ostium with concomitant
corporeal adhesions.
Table 5 American fertility society classification 1988
Classification Condition
Cavity involved <1-3 1/3 - 2/3 >2/3
1 2 3
Type of adhesions Filmy Filmy and Dense Dense
1 2 3
Menstrual pattern Normal Hypo menorrhea Amenorrhea
0 2 4
Prognostic classification HSG score Hysteroscopy
score
Stage I (Mild) 1-4
Stage II (Moderate) 5-8
Stage III (Severe) 9-12
Table 6 Clinicohysteroscopic scoring system
Hysteroscopic findings Score
Isthmic fibrosis 2
Filmy adhesions More than 50% of the cavity 1
Less than 50% of the cavity 2
Dense adhesions Single band 2
Multiple bands 4
Tubal ostium Both visualized 0
Only one visualized 2
Both not visualized 4
Tubular cavity (sound less than 6) 10
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Hysteroscopic surgery has revolutionized the treatment
of intrauterine adhesion and it is the established gold
standard technique. The magnification and the direct
view of the adhesions allow for a precise and safe treat-
ment. When the lesions are filmy, the tip of the hystero-
scope and uterine distension may be enough to break
down the adhesions [33]. Thus, in favourable cases the
restoration of cavity can be obtained through “no touch”
hysteroscopy in out-patient setting without general
anaesthesia.
Nevertheless, the treatment of the severe and dense
adhesion remains more challenging: in these cases, the
cavity may be completely occluded or too narrow to
allow the insertion of hysteroscopic sheath inside the
cervix. Moreover, multiple procedures may be required
because of post-surgical recurrence of the adhesions
[3,4,6]. In these situations, it is recommended to offer a
proper counselling regarding the lower rate of success
and the higher risk of complications.
According to many experts, the removal of the adhe-
sions should start form the lower part of the uterus and
progress toward the upper part [3]. Any central and
filmy adhesions should be separated initially in order to
allow adequate distension of the uterine cavity. Dense
and lateral adhesions should be treated at the end, bear-
ing in mind the greater risk of uterine perforation and
bleeding [4].
A wide range of mechanical or electric equipment has
been adopted during hysteroscopic adhesiolysis. Even
the use of a sharp needle (Touhy needle) has showed aTable 4 Classification by March 1978
Classification Condition
Mild Filmy adhesion occupying less than one-quarter of
uterine cavity. Ostial areas and upper fundus minimally
involved or clear.
Moderate One-fourth to three fourth of cavity involved. Ostial areas
and upper fundus partially involved. No agglutination
of uterine walls
Severe More than three fourth of cavity involved. Occlusion of
both ostial area and upper fundus. Agglutination of
uterine wallsgood rate of success. Specifically, 55 patients were
treated with a 16-gauge, 80-mm Touhy needle (Portex
Ltd., Hythe Kent, England) introduced alongside a 5-mm
hysteroscope under fluoroscopical guidance. All women
regained a normal menstruation pattern but no data
about fertility outcome was collected in this study [40].
A cold-knife approach is supposed to prevent thermal
damage of the residual endometrium and reduce the rate
of perforation during the procedure (Figure 2). The use of
powered instruments (electric surgery or laser) has also
proven efficient for hysteroscopic adhesiolysis [41-44].
Nevertheless the use of electric surgery is associated with
potential damage to the residual endometrium [3,6].Menstrual pattern Normal 0
Hypomenorrhea 4
Amenorrhea 8
Reproductive performance Good obstetrics history 0





Figure 2 Adhesiolysis done using hysteroscopic scissors.
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as bipolar one [45]. However, one of the advantages of
the latter is that the tissue effect is more focal, and the
use of electrolyte-containing uterine distension media
means that electrolyte changes are less likely to be clin-
ically serious in cases of fluid overload [45].
The treatment with laser vaporization using an Nd-YAG
(neodymium-doped yttrium aluminium garnet) and KTP
(potassium-titanyl-phosphate) laser has also been de-
scribed in the treatment of AS [46,47]. However, it is char-
acterized by higher costs and increased uterine damages,
and does not offer significant advantages over other elec-
tric equipment. Therefore its use in hysteroscopic adhe-
sions has been increasingly abandoned [48].
The most difficult cases to treat are those with severe
AS stage characterized by a complete obliteration of cav-
ity and no apparent endometrium visible at hysteros-
copy. It can be impossible to dissect the adhesions with
standards hysteroscopic techniques. In these difficult cir-
cumstances, several innovative hysteroscopic strategies
have been suggested in medical literature.
Mc Comb and Wagner in 1997 treated six cases with
severe IUA under laparoscopic control: their technique
was based on separation of uterine wall into two hemicav-
ities by inserting a 13 French Pratt cervical dilator. Subse-
quently, the residual fibrotic “septum” was cut up to the
fundus with hysteroscopic scissors. Regular menses was
achieved in all cases, five women conceived and four of
them had live births. Uterine perforation occurred in three
cases, but only one case required a further hysteroscopic
adhesiolysis [49].
Another innovative method was named by its creator
“myometrial scoring” [50]: the technique consists in cut-
ting six to eight incisions from the fundus of the uterus
to the isthmus using a knife electrode with the aim of
enlarging the uterine cavity and potentially uncovering
functional endometrium. Finally, the cervix was dilatedup to Hegar 12–18 to prevent cervical stenosis. Among
the seven women treated with this technique, five had a
normal menstrual pattern and three had conceived. More-
over, a significant reduction of the pain was achieved in
two of the four symptomatic cases.
A transcervical resectoscopy after the dilatation of cer-
vix with laminaria tent was also suggested in the treat-
ment of severe AS [51]. Laminaria are made from dried
kept stalk of the alga named “Laminaria digitata” (Shivata
Medical Products Company, Nagoya, Japan). When
inserted into the cervix, it slowly dilates it thanks to its
hydrophilic property. The first step of the procedure con-
sisted in the insertion into the cervix of one or two lami-
naria tents which were left in situ. After 24 hours they
were replaced by three or four tents inserted up to the
fundus and left in situ for further 24 hours. Finally, hyster-
oscopic resection of adhesions was carried out under
laparoscopic guidance. Prophylactic antibiotics were ad-
ministered during and after surgery. In addition, an intra-
uterine device (IUD) was placed inside the uterus and
hormonal treatment with conjugated estrogens and me-
droxyprogesterone acetate was given. All patients enrolled
in this study (n = 7) achieved normal menses and three be-
came pregnant (two live birth and one miscarriage).
Hysteroscopic treatment of AS offers good results and
resolves menstrual disturbance in the majority of cases
[45]. Data regarding reproductive outcome came, in the
majority of cases, from non randomized or prospective
studies. In addition, a critical evaluation is often challen-
ging, because of the different classification criteria and
treatment strategy adopted. An overall pregnancy rate
from 40% to 63% was previously described [4,44,45,52].
Fertility restoration after hysteroscopic treatment seems
to be influenced by several factors such as menstrual
pattern before and after the surgery, severity of adhe-
sions and adhesions recurrence rate after treatment [53].
Prevention of adhesion recurrence
As mentioned above, adhesions recurrence after surgery
is one of the most important factors which can hinder
reproductive outcome after IUA treatment. Adhesions
recurrence rate is significantly higher in those cases
where a severe AS is diagnosed [44,53] Several methods
to prevent IUA reformations after surgery have been
proposed. Nonetheless few comparative studies have
been developed [54]. This could be probably due to the
multitude treatment approach adopted and particularly
to the lack of a unified standardized classification system
for IUA diagnostic characterization.
IUD and intrauterine adhesion
The rate of IUA reformation after surgery remains high
(3.1% to 23.5%) [41,55]. These adhesions usually tend to
be thin and filmy [56]. The use of IUD in order to
Conforti et al. Reproductive Biology and Endocrinology 2013, 11:118 Page 7 of 11
http://www.rbej.com/content/11/1/118prevent adhesion recurrence was one of the first at-
tempts to be documented in literature [8].
It was speculated that an IUD could help physiological
endometrial regeneration by separating the anterior and
posterior uterine walls. Although many authors have re-
ported good results [57,58], our data is conflicting, and
there is also uncertainty about the size and the kind of
the IUD to be used. Vesce et al. used a copper IUD with
good results in 48 women with functional amenorrhea.
In a short follow-up after the insertion of the IUD, a sig-
nificant number of women regained a regular menses
[59]. Nevertheless, some authors believe that inflamma-
tory factors released by copper device could aggravate
the endometrial injury [60]. Touguc et al. found no dif-
ference in adhesion reformation among women random-
ized to receive IUD device, estrogens treatment or no
treatment after hysteroscopic septum resection [61]. The
Levonorgestrel-releasing IUD should not be used for his
suppressing effect on the endometrium [4]. The T-
shaped IUD seems to be too tiny to guarantee a stable
separation between the uterine walls [62]. With its pecu-
liar trapezoidal shape, the Lipples loop was considered
the most adequate device to prevent adhesion albeit it is
no longer available in the global market [62].
Intrauterine balloon stent
A new intrauterine stent was also described as a mech-
anical method to prevent adhesions recurrence [62]. It is
a silicon made, triangular shape device which fits the
normal triangular shape of the uterine cavity (Cook
medical Inc, Bloomington, USA). In several cases treated
for IUA in which the treatment protocol had included
intrauterine balloon stent immediately after the proced-
ure, good results in term of fertility outcome were
achieved.
Specifically, the author reported among 1240 patients
treated using intrauterine stent, pregnancy rate of 61.6%
and spontaneous miscarriage rate of 15.6% [62].
No data about IUA recurrence was reported. The au-
thor recommends prophylactic broad-spectrum anti-
biotic until the stent remains inside uterine cavity.
In a recent cohort retrospective study of 107 patients
with AS, the use of intrauterine ballon stent, compared
with IUD and hyaluronic acid, resulted in significantly
higher reduction of adhesions recurrence rate [63].
Although this encouraging evidence, data about its
safety and efficacy seem still insufficient.
Foley catheter
The Foley catheter was one of first mechanical devices
used to separate the uterine walls preventing the recur-
rence of the IUA [2,35,64]. In a study involving 25 cases
with moderate and severe adhesions, a fresh amnion
graft over a Foley’s catheter balloon was inserted intothe uterus for two weeks after hysteroscopic surgery. Al-
though uterine perforation occurred in two cases, thus
confirming the potential damage caused by this ap-
proach, a significant improvement in uterine length was
found with no adhesion reformation in group with mod-
erate adhesion [65].
The use of Foley’s catheter has also been compared
with IUD as an adjunctive therapy in AS. While the IUD
was removed after the third vaginal bleeding, the cath-
eter was maintained inside the uterus for ten days. The
group treated with Foley’s catheter showed higher con-
ception rate compared with the IUD group (33.9% ver-
sus 22.5%). In addition, the 81% of women restored their
normal menstrual pattern [66].
However encouraging, there are no randomized con-
trolled trials attesting the Foley’s catheter efficacy in the
prevention of IUA. The main concerns about this
method are uterine perforation, ascending infection from
vagina and the high discomfort.
Hyaluronic acid and other anti-adhesion barriers
Hyaluronic acid is one of the most widespread compo-
nent in human tissue and it is involved in many biological
function such as mechanical support, cell migration and
proliferation. In the last decades, products derived from
hyaluronic acid have been adopted in gynaecologic sur-
gery to prevent both intraperitoneal and intrauterine
adhesions [67-69].
The mechanism by which these products act is not
completely understood. Hyaluronic acid generates a
temporary barrier between organs which mechanically
obstacles adhesions formation; in addition, these prod-
ucts influence peritoneal tissue repair by increasing the
proliferation rate of mesothelian cells [70].
Among hyaluronic based products, ferric hyaluronic
acid was removed from the market due to its toxicity in
2003 [69].
Autocross-linked hyaluronic acid (Hyalobarrier©) is a
new anti-adhesion barrier capable of preventing adhe-
sion formation after gynaecological surgery (Fidia Ad-
vanced Biopolymers SRL, Padova, Italy) [71]. It is a
highly viscous gel formed by the autocross-linked con-
densation of hyaluronic acid, and a recent systematic
review confirmed that it can prevent intraperitoneal ad-
hesion after laparoscopic myomectomy and intrauterine
adhesions after hysteroscopical procedure [72].
Another anti-adhesion barrier characterized by chem-
ically modified hyaluronic acid (sodium hyaluronate)
and carboxymethylcellulose (Seprafilm©) was used for
prevention of IUA (Genzyme Corporation, Cambridge,
MA, USA). In a randomized controlled blind study in-
volving 150 patients who underwent surgical evacuation
or curettage after missed or incomplete abortion, the
rate of IUA in the treated group was low compared with
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about long term clinical outcome, including fertility [74].
A brand new hyaluronic acid derived (alginate car-
boxymethylcellulose hyaluronic acid) was evaluated in a
prospective randomized trial including 187 cases. Four
weeks after surgery, intrauterine adhesions were signifi-
cantly lower compared with carboxymethylcellulose hya-
luronic acid [75].
Restoration of normal endometrium
Medical therapy
In order to restore basal endometrium and rebuild the
normal endometrial layer inside the uterine cavity many
authors have proposed hormonal treatment [33,62,76].
Many different treatments have been suggested and
there is no shared consensus about the time of the ad-
ministration (preoperative and/or postoperative) and the
type of regimen (oestradiol or combined oestradiol and
progesterone). The general idea is to encourage fast
growth of any residual endometrium immediately after
surgery with the dual purpose of preventing new scar
formation and restoring a normal uterine environment.
It is supposed that this goal can only be achieved with
supraphysiological hormonal levels.
Myers et al. proposed a prolonged preoperative and a
postoperative treatment with estrogens in 12 subjects with
severe amenorrhea. All women resumed a normal men-
strual pattern and six of them become pregnant [77].
March et al. suggested a treatment with micronized
oestradiol, 2 mg twice daily for 30–60 days and medrox-
yprogesterone acetate 10 mg per day at last 5 days of
oestrogen therapy [62].
Other authors prescribed estradiolvalerate 4 mg per
day for 4 weeks and medroxyprogesterone acetate,
10 mg per day at last two week of treatment [3]. There
is evidence that oestrogen-progestin treatment after cur-
ettage for post-partum haemorrhage or incomplete abor-
tion increases endometrial thickness. Specifically, 60
women were randomized to receive estradiolvalerate
2 mg for 21 days and norgestrel 0.5 mg in the last
10 days of oestrogen treatment. 21–26 days after curet-
tage all women underwent a transvaginal ultrasound.
The endometrial thickness, width and volume were re-
ported significantly elevated in the treated group [78].
The use of sildenafil citrate intravaginally was docu-
mented as possible pharmacological treatment to restore
endometrial thickness. This drug is a type 5 specific
phosphodiesterase inhibitor that enhances vasodilator ef-
fect of nitric oxide (NO) whose synthase isoforms were
also found in the uterus [79]. In a prospective observa-
tional study, sildenafil citrate improved endometrial
thickness in 92% of cases who presented thin endomet-
rium (endometrial thickness <8 mm) [80]. Other encour-
aging results came from IVF where the combination ofoestradiol and sildenafil citrate improved endometrial
blood flow and endometrial thickness in 4 women with
prior failed assisted reproductive cycles due to poor
endometrial response [79]. There are only two case re-
ports concerning the use of sildenafil in AS. Endometrial
thickness significantly improved with treatment, and
both women become pregnant after the first treatment
cycle [81].
Stem cells and endometrial regeneration
Endometrial tissue had an intrinsic capacity of regener-
ation. Endometrial regeneration normally occurs after
menstruation and delivery. There is substantial evidence
in literature that adult endometrial tissue contains epi-
thelial progenitor cells and mesenchymal/stromal (MSC)
cells [82]. These cells could be the target of a specific
therapy in order to regenerate the endometrial tissue in
cases of dysfunctional or atrophic endometrium. Re-
cently, a case report of a severe AS treated with autolo-
gous stem cells isolated from the women’s own bone
marrow has been described [83]. The woman had a his-
tory of infertility and hypomenorrhea following a D&C
in 2005. She was treated hysteroscopically for severe
intrauterine adhesions, and a T-shaped IUD was placed
inside the uterus for six months. During this time, she
also received therapy with combined oestrogen and pro-
gesterone (ethinylestradiol 0.05 mg from fifth to 25th
day of the cycle and medroxyprogesterone acetate 10 mg
from 20th to 25th day). Finally, after failure of hormonal
therapy in restoring endometrium, endometrial stem
cells were implanted inside the uterus after curettage on
the second day of menstrual cycle. A clinical pregnancy
was obtained after a heterologous embryo transfer.
These pioneering discoveries could open a new scenario
in the management of AS, although more evidences are
mandatory.
Post-operative assessment
Evaluation of uterine cavity after adhesiolysis is an im-
portant step in AS management. As mentioned before,
complete resolution of the adhesions is not always pos-
sible with a single procedure, especially in severe stages
where a high recurrence rate is documented. For in-
stance, Valle and Sciarra reported a 50% and 21.6% of re-
currence in severe and moderate AS respectively [41].
Timely recognition of any recurrence of adhesions is es-
sential to provide the best prognosis, therefore it may be
necessary to repeat surgery. For this reason, most treat-
ment protocols include a follow-up to assess endomet-
rial restoration after the surgery. If this is not done,
there is evidence of an increased obstetric risk [62]. Al-
though the restoration of menses is considered a good
marker of success, other diagnostic investigations are
fundamental for an exhaustive evaluation.
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management. Usually, post-treatment assessment of the
uterine cavity is recommended one-two months after
the initial surgery [54]. Ultrasound, HSG and hysteros-
copy are the most common follow-up methods.
Ultrasound is an accurate and cost-effective tool for
measuring endometrial thickness and for the evalu-
ation of normal endometrial development during men-
strual cycle. HSG has the advantage to check tubal
patency, and at the same time it can help in the reso-
lution of thin adhesions from pressure of the liquid
contrast medium. Hysteroscopy, however, remains the
only method which allows an accurate estimation of
adhesion recurrence and it is the most commonly used
in clinical practice. Of course, it also allows further in
office adhesiolysis.
Conclusions
AS is a condition with a high impact on female repro-
duction. Even in women who conceive after AS treat-
ment, a scrupulous surveillance should be carried out
for the high risk of placental anomalies [3,5,62] and
much effort should be devoted to the prevention. Con-
sidering that the highest incidence is reported after mis-
carriage curettage, a significant reduction of these
procedure could lead to a lower incidence of AS. Specif-
ically, the surgical removal of embryo placental retained
product in condition such as incomplete or missed mis-
carriage should be performed conscientiously and, in
favourable cases, a less invasive approach should be con-
sidered [3]. For example hysteroscopy could be an effect-
ive method for selective removal of placental retained
tissue with good results in terms of pregnancy rate and
IUA prevention [84]. Specifically, in a cohort study in-
volving 95 patients, conception rate, time to conception
and intrauterine adhesions was lower in the group
treated hysteroscopically [84]. In addition, medical ap-
proach to miscarriage seems to significantly reduce the
incidence of IUA [85]. Recent meta-analysis evaluating
the safety and the effectiveness of medical treatment
both for first trimester and incomplete miscarriage con-
cluded that medical strategies are a valuable alternative
to curettage [86,87].
The introduction of hysteroscopy has significantly im-
proved the fertility outcome and the treatment success
rate [3,4,62]. Nevertheless, AS recurrence rates remain
high, and we must continue to look for techniques
which reduce the formation of new adhesions.
IUD, uterine stent, adhesions barriers and hormonal
treatment have proven efficient, yet more comparative
trials are needed. A novel approach, based on endomet-
rial stem cells and the understanding of physiopathologic
mechanism involved in endometrial regeneration, could
represent a worthwhile area for a future research.Abbreviations
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